Home >> The CSGKC is a projec 上海会所orward-looking vision

The CSGKC is a projec 上海会所orward-looking vision

Saturday, July 20th, 2019 | weimiaow | 上海会所

 which provides support to Guangdong province and the Guangdong-Hong Kong-Macao Greater Bay Area. It is an impo

rtant platform to deepen cooperation between China and Singapore,” noted Heng Swee Keat, Singa 上海会所品茶微信

pore’s deputy prime minister and finance minister, when he and his team visited CSGKC in May.

 上海会所With joint effort, the CSGKC maintains growth and embodies

ecological protection. The combination will attract professionals, he added.

Greeting Heng’s delegation, Zhang Shuofu, Party secretary of Guangzhou, said th 上海会所品茶微信

at the two sides will deepen cooperation in scientific innovation, emergin

 上海会所g industries, education, culture and ecological environment. They will also promote the collaboration of indust

ries and smart cities, to build the CSGKC into a highland of knowledge innovation.

Designated as a major innovation platform in the Bay Area, the CSGKC has gained much development in nine years. 上海会所品茶微信

According to official statistics, the CSGKC has attracted 1,524 companies with registered capital totaling 133.4 billion yuan

($19.39 billion). It also completed investments in fixed assets worth 106.2 billion yuan. 上海会所

Among them are CanSemi Technology, a 12-inch wafer chip supplier to be operational soon, equipment manufa

 上海会所品茶微信cturer Greatoo Intelligent Equipment, biopharmaceuticals company BeiGene and other big names.

Collectively, they have launched 165 projects – 48 of w

hich are under construction – with a total investment of 77 billion yuan. 上海会所品茶微信

Cooperation with international companies is boosting the development of the biomedicine industry in the CSGKC.

Earlier this month, the CSGKC administrative committee signed an agreement with Tessa Therapeutics in Sin 上海会所

gapore for the latter to set up its China pharmaceuticals headquarters. The agree

 上海会所品茶微信ment focuses on the research and development, production and sales of innovative immunotherapy.

Tessa will invest $120 million in the project. They will set up teams to launch clinical tests and strengthen the biomedic 上海会所品茶微信

al innovation chain in Guangzhou, according to Andrew Khoo, co-founder and CEO of Tessa.

ashddd.com